MedTrace Logo

BEAT AF - Braking Ectopic Atrial Trends In Atrial Fibrillation

NCT05872776 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-06-20

No results posted yet for this study

Summary

Paroxysmal AF subjects with a documented ECG event of AF will be recruited to the study To assess the efficacy of CardiaCare™ RR2 wearable home-care neuromodulation system in reducing AF burden and symptoms in Paroxysmal AF patients

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

DEVICE

Neuromodulation with RR2 device

non-invasive neuromodulation with RR2 device

DEVICE

Mock sham neuromodulation with sham RR2 device

Mock sham stimulation with RR2 device

Sponsors & Collaborators

  • Ziv HealthCare Ltd.

    lead INDUSTRY

Principal Investigators

  • Ehud Chorin, MD · Tel Aviv Souraski Medical Center, Department of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-16
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872776 on ClinicalTrials.gov